Neurology Clinical Trials

Statistical methods in neurology trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All neurology trials

816 results

• “Completeness of Response” Following Treatment With Treximet™ for Migraine: Complete Statistical AnalysisIndependent statistical analysis of "Completeness of Response" Following Treatment With Treximet™ for Migraine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00893737).Phase 4Results postedn = 147NCT00893737
• (DECIDE)Complete statistical analysis of the phase 3 DECIDE trial comparing BIIB019 (daclizumab high yield process) with interferon beta-1a in participants with relapsing-remitting multiple sclerosis, including trial design, registered endpoints, regression methods, efficacy…Phase 3Results postedn = 1,841NCT01064401
• [F-18] Fluorothymidine (FLT) Imaging on Patients With Primary Brain Tumors: Complete Statistical AnalysisIndependent statistical analysis of [F-18] Fluorothymidine (FLT) Imaging on Patients With Primary Brain Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00707343).Phase 1Results postedn = 15NCT00707343
• 1% Chloroprocaine(PF) vs. Bupivacaine Spinals: Complete Statistical AnalysisIndependent statistical analysis of 1% Chloroprocaine(PF) vs. Bupivacaine Spinals: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03324984).Phase 2Results postedn = 110NCT03324984
• 18F-AV-1451 Autopsy Study: Complete Statistical AnalysisIndependent statistical analysis of 18F-AV-1451 Autopsy Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02516046).Phase 3Results postedn = 156NCT02516046
• 2 Dose Neuraxial Morphine for Prevention of PDPH: Complete Statistical AnalysisIndependent statistical analysis of 2 Dose Neuraxial Morphine for Prevention of PDPH: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02473276).Phase 4Results postedn = 44NCT02473276
• 2CAREIndependent statistical analysis of Coenzyme Q10 in Huntington's Disease (HD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00608881).Phase 3Results postedn = 609NCT00608881
• 306A/306BIndependent statistical analysis of A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 225NCT01176240
• 32543Independent statistical analysis of Effect of Montelukast Therapy in Obstructive Sleep Apnea(OSA) Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01027806).Phase 4Results postedn = 64NCT01027806
• A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720: Complete Statistical AnalysisIndependent statistical analysis of A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 4Results postedn = 42NCT01578330
• A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome: Complete Statistical AnalysisIndependent statistical analysis of A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children…Phase 3Results postedn = 87NCT02926898
• A 24-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease: Complete Statistical AnalysisIndependent statistical analysis of A 24-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 5NCT00283933
• A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients: Complete Statistical AnalysisIndependent statistical analysis of A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 375NCT02589275
• A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features: Complete Statistical AnalysisIndependent statistical analysis of A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features: primary endpoint results,…Phase 3Results postedn = 901NCT03573297
• A Clinical Study Examining the Safety and Effectiveness of a New Medication (Keppra®) for the Prevention of Migraine Headaches: Complete Statistical AnalysisIndependent statistical analysis of A Clinical Study Examining the Safety and Effectiveness of a New Medication (Keppra®) for the Prevention of Migraine Headaches: primary endpoint results, effect estimate with confidence interval, sample-size…Phase NAResults postedn = 31NCT00203216
• A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment: Complete Statistical AnalysisIndependent statistical analysis of A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 2Results postedn = 96NCT00617461
• A Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD): Complete Statistical AnalysisIndependent statistical analysis of A Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD): primary endpoint results, effect estimate with confidence interval, sample-size…Phase 3Results postedn = 35NCT03852498
• A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain: Complete Statistical AnalysisIndependent statistical analysis of A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 3Results postedn = 681NCT03213457
• A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN): Complete Statistical AnalysisIndependent statistical analysis of A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN):…Phase 2Results postedn = 141NCT02215252
• A Comparative Study of JNS013 in Participants With Post-Tooth-Extraction Pain: Complete Statistical AnalysisIndependent statistical analysis of A Comparative Study of JNS013 in Participants With Post-Tooth-Extraction Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00737048).Phase 3Results postedn = 328NCT00737048
• A Comparison of Propofol Versus Midazolam to Sedate Critically Brain Injury; Measurement of Cytokine Response and Assessment of Function: Complete Statistical AnalysisIndependent statistical analysis of A Comparison of Propofol Versus Midazolam to Sedate Critically Brain Injury; Measurement of Cytokine Response and Assessment of Function: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 4Results postedn = 1NCT01712477
• A Comparison of Proprietary Formulations of Oral Ketamine + Aspirin and Oral Ketamine Alone for Musculoskeletal Pain: Complete Statistical AnalysisIndependent statistical analysis of A Comparison of Proprietary Formulations of Oral Ketamine + Aspirin and Oral Ketamine Alone for Musculoskeletal Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 4Results postedn = 60NCT04860804
• A Dose Ranging Effect of Preoperative Diphenhydramine on Postoperative Quality of Recovery After Ambulatory Surgery: Complete Statistical AnalysisIndependent statistical analysis of A Dose Ranging Effect of Preoperative Diphenhydramine on Postoperative Quality of Recovery After Ambulatory Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 90NCT01451762
• A Drug-drug Interaction Study With Risdiplam Multiple Dose and Midazolam in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of A Drug-drug Interaction Study With Risdiplam Multiple Dose and Midazolam in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1Results postedn = 35NCT03988907
• A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer’s Disease (TRAILBLAZER-EXT): Complete Statistical AnalysisIndependent statistical analysis of A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 95NCT04640077
• A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004 (Patidistrogene Bexoparvovec) in Participants With Limb-Girdle Muscular Dystrophy, Type 2D (LGMD2D): Complete Statistical AnalysisIndependent statistical analysis of A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004 (Patidistrogene Bexoparvovec) in Participants With Limb-Girdle Muscular Dystrophy, Type 2D (LGMD2D): primary endpoint results, effect estimate with…Phase 1/2Results postedn = 6NCT01976091
• A Home-based Training Program for Elderly Patients With Dementia: Complete Statistical AnalysisIndependent statistical analysis of A Home-based Training Program for Elderly Patients With Dementia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02667951).Phase NAResults postedn = 129NCT02667951
• A Long Term Follow up Administration Study of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset Seizures: Complete Statistical AnalysisIndependent statistical analysis of A Long Term Follow up Administration Study of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset Seizures: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 398NCT00367432
• A Long-term Efficacy and Safety Study of Tramadol Hydrochloride Plus Acetaminophen (JNS013) in Japanese Participants With Chronic Pain: Complete Statistical AnalysisIndependent statistical analysis of A Long-term Efficacy and Safety Study of Tramadol Hydrochloride Plus Acetaminophen (JNS013) in Japanese Participants With Chronic Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 219NCT00736957
• A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis: Complete Statistical AnalysisIndependent statistical analysis of A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 137NCT01610687
• A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine: Complete Statistical AnalysisIndependent statistical analysis of A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02025556).Phase 2Results postedn = 297NCT02025556
• A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH: Complete Statistical AnalysisIndependent statistical analysis of A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 16NCT03048747
• A Multicenter, Safety and Efficacy Study of Taliglucerase Alfa in Subjects With Type 3 Gaucher Disease: Complete Statistical AnalysisIndependent statistical analysis of A Multicenter, Safety and Efficacy Study of Taliglucerase Alfa in Subjects With Type 3 Gaucher Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 4Results postedn = 14NCT04002830
• A Multidomain Intervention Program for Older People With Dementia: Complete Statistical AnalysisIndependent statistical analysis of A Multidomain Intervention Program for Older People With Dementia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04948450).Phase NAResults postedn = 60NCT04948450
• A Natural History Study In Chinese Male Patients With Duchenne Muscular Dystrophy: Complete Statistical AnalysisIndependent statistical analysis of A Natural History Study In Chinese Male Patients With Duchenne Muscular Dystrophy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 312NCT03760029
• A Non-invasive Intervention (BreEStim) for Management of Phantom Limb Pain (PLP) After Limb Amputation (Experiment 1): Complete Statistical AnalysisIndependent statistical analysis of A Non-invasive Intervention (BreEStim) for Management of Phantom Limb Pain (PLP) After Limb Amputation (Experiment 1): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 15NCT04750525
• A Non-Invasive Neuromodulation Device for Treatment of Migraine Headache: Complete Statistical AnalysisIndependent statistical analysis of A Non-Invasive Neuromodulation Device for Treatment of Migraine Headache: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01899040).Phase NAResults postedn = 100NCT01899040
• A Novel Approach for Brain Stimulation in Severe Stroke: Complete Statistical AnalysisIndependent statistical analysis of A Novel Approach for Brain Stimulation in Severe Stroke: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03868410).Phase EARLY_1Results postedn = 16NCT03868410
• A Patient-facing Tool to Reduce Opioid-Psychotropic Polypharmacy in People Living With Dementia (PLWD): Complete Statistical AnalysisIndependent statistical analysis of A Patient-facing Tool to Reduce Opioid-Psychotropic Polypharmacy in People Living With Dementia (PLWD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 129NCT05628181
• A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007): Complete Statistical AnalysisIndependent statistical analysis of A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 195NCT01657370
• A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS: Complete Statistical AnalysisIndependent statistical analysis of A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05053035).Phase 2Results postedn = 5NCT05053035
• A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG): Complete Statistical AnalysisIndependent statistical analysis of A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 12NCT03759366
• A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS): Complete Statistical AnalysisIndependent statistical analysis of A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 3Results postedn = 38NCT01377922
• A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson’s Disease Patients: Complete Statistical AnalysisIndependent statistical analysis of A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 244NCT02337725
• A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults: Complete Statistical AnalysisIndependent statistical analysis of A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults: primary endpoint results, effect estimate with confidence interval,…Phase 3Results postedn = 18NCT01478347
• A Phase III Study of Eszopiclone in Patients With Insomnia (Study SEP 190-150): Complete Statistical AnalysisIndependent statistical analysis of A Phase III Study of Eszopiclone in Patients With Insomnia (Study SEP 190-150): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 369NCT00770692
• A Pilot Study of a Non-Invasive Neuromodulation Device for Treatment of Parkinson’s Disease: Complete Statistical AnalysisIndependent statistical analysis of A Pilot Study of a Non-Invasive Neuromodulation Device for Treatment of Parkinson's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 6NCT02134795
• A Pilot Study of Suvorexant for Insomnia in Parkinson Disease: Complete Statistical AnalysisIndependent statistical analysis of A Pilot Study of Suvorexant for Insomnia in Parkinson Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02729714).Phase 4Results postedn = 21NCT02729714
• A Pilot Study on Diurnal Variation: Complete Statistical AnalysisIndependent statistical analysis of A Pilot Study on Diurnal Variation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01806051).Phase NAResults postedn = 6NCT01806051
• A Pilot Study to Assess Effects of Self-Administered Nitrous Oxide (SANO) on Urodynamic Study (UDS) Parameters: Complete Statistical AnalysisIndependent statistical analysis of A Pilot Study to Assess Effects of Self-Administered Nitrous Oxide (SANO) on Urodynamic Study (UDS) Parameters: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 4Results postedn = 19NCT05883332

← All therapeutic areas